Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France
NCT ID: NCT04325646
Last Updated: 2023-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5000 participants
OBSERVATIONAL
2020-03-13
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many questions are being asked about this new virus and the infection it causes, including questions about the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of Patients With COVID-19.
NCT05107245
SARS-CoV-2 in Stools Compared to Respiratory Viral Strains.
NCT05567419
WGS Analysis of COVID-19 Positive Patients
NCT04353401
Viral and Microbial Circulation Between Humans, Domesticated and Wild Animals Along an Ecotone, Democratic Republic of Congo
NCT04012164
COVID-19 Persistence in Stool
NCT04546776
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many questions are being asked about this new virus and the infection it causes, including questions about the transition from animal to human occur, the beginning of viral circulation in humans, the period of contagiousness, the percentage of asymptomatic and pauci-symptomatic forms. Serological studies can provide answers to these questions. There is no serological test for SARS-COV-2 yet, but the laboratory of respiratory infection viruses at the Institut Pasteur is working on its development.
This study proposes to carry out a collection of samples taken from subjects who travelled to China before the epidemic outbreak or suspected of being infected with SARS-CoV-2.
As soon as it is available, serology will be performed on the collected samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CORSER-1a
Subjects who had been to China in the weeks before the outbreak began
Human Biological samples
Blood samples for serological tests
CORSER-1b
Subject who had a clinical profile compatible with an SARS-CoV-2 infection between August 1, 2019 and February 29, 2020
Human Biological samples
Blood samples for serological tests
CORSER-2a
Subjects with suspected CoV-2-SARS infection with negative results from RT-PCR testing of respiratory specimens
Human Biological samples
Blood samples for serological tests
CORSER-2b
Contacts or co-exposures of confirmed CoV-2-SARS infection cases, or who have worked or stayed in a hospital where confirmed CoV-2-SARS infection has been managed
Human Biological samples
Blood samples for serological tests
CORSER-2c
Subjects who have been exposed to a risk of infection with SARS-CoV-2 in a geographical area of SARS-CoV-2 circulation.
* study among pupils, their parents and siblings, as well as teachers and non-teaching staff of a high-school located in Oise
* study among pupils from 5 to 12 and their parents in elementary schools located in Oise
* study among choir members
Human Biological samples
Blood samples for serological tests
CORSER-2d
Staff of health care institutions
Human Biological samples
Blood samples for serological tests
CORSER-2e
Subjects in care, hospitalized or residing in health care facilities
Human Biological samples
Blood samples for serological tests
CORSER-3
Subjects returning from a humanitarian mission that started before 31/01/2020
Human Biological samples
Blood samples for serological tests
CORSER-2f
Subjects with two symptomatic episodes of SARS-CoV-2 infection
Human Biological samples
Blood samples, saliva, nasopharyngeal swab for serological tests
CORSER-4
Subjects being vaccinated against COVID-19
Human Biological samples
Blood samples, saliva, nasopharyngeal swab for serological tests
CORSER-5
Subjects with acute SARS-CoV-2 infection and uninfected controls
Human Biological samples
Blood samples, saliva, nasopharyngeal swab for serological tests
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human Biological samples
Blood samples for serological tests
Human Biological samples
Blood samples, saliva, nasopharyngeal swab for serological tests
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* State of health compatible with a blood sample as defined in the protocol
Exclusion Criteria
* Have had an infectious episode and/or respiratory signs in the 14 days prior to the scheduled visit (CORSER 1 and 2a, 2b)
* Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days prior to the date of the visit.(CORSER 1 and 2a, 2b)
5 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruno HOEN, Pr
Role: PRINCIPAL_INVESTIGATOR
Institut Pasteur
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens-Picardie
Amiens, , France
EHPAD Villa Concorde
Asnières-sur-Seine, , France
CHU François Mitterand
Dijon, , France
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, , France
CHU Limoges
Limoges, , France
Hôpital de la Croix Rousse
Lyon, , France
EHPAD Les Etangs
Mennecy, , France
CHRU de Nancy
Nancy, , France
Hôpitaux de Brabois
Nancy, , France
CHR Orléans
Orléans, , France
Institut Mutualiste
Paris, , France
Centre Médical de l'Institut Pasteur
Paris, , France
Institut Pasteur
Paris, , France
EHPAD Villa Lecourbe
Paris, , France
Hôpital la Pitié Salpetrière
Paris, , France
CHU Poitiers
Poitiers, , France
Hôpital Pontchaillou
Rennes, , France
CHU Saint-Etienne
Saint-Etienne, , France
CHRU de Strasbourg
Strasbourg, , France
CH de Tourcoing
Tourcoing, , France
Hôpital Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garcia L, Woudenberg T, Rosado J, Dyer AH, Donnadieu F, Planas D, Bruel T, Schwartz O, Prazuck T, Velay A, Fafi-Kremer S, Batten I, Reddy C, Connolly E, McElheron M, Kennelly SP, Bourke NM, White MT, Pelleau S. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses. 2022 Jul 8;14(7):1491. doi: 10.3390/v14071491.
Benetos A, Lai TP, Toupance S, Labat C, Verhulst S, Gautier S, Ungeheuer MN, Perret-Guillaume C, Levy D, Susser E, Aviv A. The Nexus Between Telomere Length and Lymphocyte Count in Seniors Hospitalized With COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e97-e101. doi: 10.1093/gerona/glab026.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.